



ASH 2025

67th ASH Annual Meeting and Exposition

December 6–9, 2025
Orlando, United States



TOP ABSTRACTS

To help navigate the exciting content being presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in GvHD.

ASH 2025: Top abstracts in GvHD

December 6–9, 2025

Oral presentations: Saturday, December 6

Abstract	Title	Presenter	Time (EST)
111 View	Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center phase 1 study	Alejandro Villar-Prados	10:00–10:15
272 View	Safety and feasibility of 0.6 mg/kg every 4 weeks dosing of axatilimab in patients treated in the AGAVE-201 study	Nosha Farhadfar	14:15–14:30
274 View	Primary results from EQUATOR, a phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease	John Koreth	14:45–15:00
276 View	First-in-human trial of allogeneic CD6-CAR Tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation	Amandeep Salhotra	15:15–15:30

Oral presentations: Sunday, December 7

Abstract	Title	Presenter	Time (EST)
514 View	Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL	Alfonso Molina	10:15–10:30

Oral presentations: Monday, December 8

Abstract	Title	Presenter	Time (EST)
817 View	MaaT013 for ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement: Results from the ARES phase III trial	Florent Malard	10:30–10:45
931 View	Post-transplant cyclophosphamide based GvHD prophylaxis in HLA-matched related and unrelated donor hematopoietic cell transplantation in adults with hematologic malignancies undergoing myeloablative conditioning: A CIBMTR analysis of 8,272 participants	Pashna Munshi	14:45–15:00
932 View	Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies	Samer Srouf	15:00–15:15
934 View	Outcomes after bone marrow versus peripheral blood mismatched unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GvHD prophylaxis	Amir Kasaeian	15:30–15:45
935 View	Post-transplant cyclophosphamide-based graft-versus-host disease (GvHD) prophylaxis is associated with a low incidence of fibrotic chronic GvHD after allogeneic hematopoietic cell transplantation across diverse donor types	Klara Kim	15:45–16:00

936 View	Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study	Steven Devine	16:00–16:15
---------------------------	--	---------------	-------------

Posters			
Abstract	Title	Presenter	Date and time (EST)
2446 View	Clinical and disease characteristics of initial participants at time of enrollment in THRIVE, a prospective, observational cohort study of patients at risk for chronic graft versus host disease	Catherine Lee	Saturday, December 6; 17:30–19:30
2462 View	Anti-inflammatory drug pegtarazimod (RLS-0071) demonstrates clinical improvement in lower gastrointestinal acute graft-versus-host disease (aGvHD) and target engagement of key inflammatory marker myeloperoxidase (MPO)	Robert Zeiser	Saturday, December 6; 17:30–19:30
2464 View	Day 7 Mount Sinai Acute GvHD International Consortium (MAGIC) algorithm probability predicts GvHD and non-GvHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients	Sunmin Park	Saturday, December 6; 17:30–19:30
2467 View	Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety	Jingtao Chen	Saturday, December 6; 17:30–19:30
2470 View	Clinically meaningful improvement of the modified Lee symptom score in patients treated with belumosudil for steroid-refractory chronic GvHD: Evidence from Canadian real-world outcomes	Sergio Rodriguez-Rodriguez	Saturday, December 6; 17:30–19:30
2477 View	Orca-T improves chronic graft-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, phase 3 trial	Everett Meyer	Saturday, December 6; 17:30–19:30
2494 View	Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GvHD in myeloablative HLA-matched allogeneic transplantation	Alfonso Molina	Saturday, December 6; 17:30–19:30
4232 View	Phase II study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion study	Steven Devine	Sunday, December 7; 18:00–20:00
4237 View	Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical trial	Yawei Zheng	Sunday, December 7; 18:00–20:00

4239 View	Multicenter real-world experience of belumosudil treatment in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: Clinical outcomes and risk factor analysis for failure-free survival	Sergio Rodriguez-Rodriguez	Sunday, December 7; 18:00–20:00
4256 View	Trial in progress: A phase 3, randomized, double-blind, placebo-controlled study of axatilimab and corticosteroids as initial treatment for moderate to severe chronic graft-versus-host disease	Zachariah DeFilipp	Sunday, December 7; 18:00–20:00
6004 View	Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the ROCKstar study	Zachariah DeFilipp	Monday, December 8; 18:00–20:00
6008 View	Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program	Leyla Shune	Monday, December 8; 18:00–20:00
6010 View	Long-term treatment duration and safety of axatilimab among patients with chronic graft-versus-host disease in AGAVE-201	Carrie Kitko	Monday, December 8; 18:00–20:00
6012 View	Axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic graft-versus-host disease: Interim safety analysis of a phase 2, randomized study	Robert Zeiser	Monday, December 8; 18:00–20:00



#ASH25

Follow us on X to keep up to date
with the latest from the congress

@GvHD_Hub



Brought to you by

